AU3999201A - 1,5-disubstituted-3,4-dihydro-1h-pyrimido(4,5-d)pyrimidin-2- one compounds and their use in treating CSBP/P38 kinase mediated diseases - Google Patents

1,5-disubstituted-3,4-dihydro-1h-pyrimido(4,5-d)pyrimidin-2- one compounds and their use in treating CSBP/P38 kinase mediated diseases

Info

Publication number
AU3999201A
AU3999201A AU3999201A AU3999201A AU3999201A AU 3999201 A AU3999201 A AU 3999201A AU 3999201 A AU3999201 A AU 3999201A AU 3999201 A AU3999201 A AU 3999201A AU 3999201 A AU3999201 A AU 3999201A
Authority
AU
Australia
Prior art keywords
pyrimido
pyrimidin
disubstituted
dihydro
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU3999201A
Other languages
English (en)
Inventor
Jerry L Adams
Jeffrey C Boehm
Ralph F Hall
John J Taggart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU3999201A publication Critical patent/AU3999201A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
AU3999201A 2000-03-02 2001-03-02 1,5-disubstituted-3,4-dihydro-1h-pyrimido(4,5-d)pyrimidin-2- one compounds and their use in treating CSBP/P38 kinase mediated diseases Pending AU3999201A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18641900P 2000-03-02 2000-03-02
PCT/US2001/006688 WO2001064679A1 (en) 2000-03-02 2001-03-02 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases

Publications (1)

Publication Number Publication Date
AU3999201A true AU3999201A (en) 2001-09-12

Family

ID=22684876

Family Applications (2)

Application Number Title Priority Date Filing Date
AU3999201A Pending AU3999201A (en) 2000-03-02 2001-03-02 1,5-disubstituted-3,4-dihydro-1h-pyrimido(4,5-d)pyrimidin-2- one compounds and their use in treating CSBP/P38 kinase mediated diseases
AU2001239992A Ceased AU2001239992B2 (en) 2000-03-02 2001-03-02 1,5-disubstituted-3,4-dihydro-1H-pyrimido[4,5-D]pyrimidin-2- one compounds and their use in treating CSBP/P38 kinase mediated diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001239992A Ceased AU2001239992B2 (en) 2000-03-02 2001-03-02 1,5-disubstituted-3,4-dihydro-1H-pyrimido[4,5-D]pyrimidin-2- one compounds and their use in treating CSBP/P38 kinase mediated diseases

Country Status (25)

Country Link
EP (1) EP1265900B1 (https=)
JP (1) JP2003525295A (https=)
KR (1) KR100806978B1 (https=)
CN (1) CN100482664C (https=)
AR (2) AR030053A1 (https=)
AT (1) ATE362473T1 (https=)
AU (2) AU3999201A (https=)
BR (1) BR0108715A (https=)
CA (1) CA2402092C (https=)
CY (1) CY1106816T1 (https=)
CZ (1) CZ20022933A3 (https=)
DE (1) DE60128457T2 (https=)
DK (1) DK1265900T3 (https=)
ES (1) ES2287107T3 (https=)
HU (1) HUP0204431A3 (https=)
IL (3) IL151426A0 (https=)
MX (1) MXPA02008588A (https=)
MY (1) MY141144A (https=)
NO (1) NO326409B1 (https=)
NZ (1) NZ520914A (https=)
PL (1) PL358280A1 (https=)
PT (1) PT1265900E (https=)
TW (1) TWI290926B (https=)
WO (1) WO2001064679A1 (https=)
ZA (1) ZA200207017B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763839B2 (en) 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1233951B1 (en) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE521353T1 (de) * 2000-10-23 2011-09-15 Glaxosmithkline Llc Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
EP1345603A4 (en) * 2000-12-20 2004-09-08 Merck & Co Inc (HALO-BENZO-CARBONYL) HETEROCYCLO-CONDENSED PHENYL-P38-KINASE INHIBITING AGENTS
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
EP2258687B1 (en) 2002-02-12 2012-12-26 Glaxosmithkline LLC Nicotinamide derivates useful as P38 inhibitors
KR100608414B1 (ko) 2002-02-13 2006-08-02 에프. 호프만-라 로슈 아게 신규한 피리딘- 및 피리미딘-유도체
KR20040103972A (ko) * 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
GB0218800D0 (en) * 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
EP1539121A4 (en) 2002-08-29 2008-08-13 Scios Inc METHOD OF REQUESTING OSTEOGENESIS
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
AU2003291310A1 (en) 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2006522756A (ja) 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミド化合物
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7569571B2 (en) * 2003-12-23 2009-08-04 Novartis Ag Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators
AU2005316668B2 (en) * 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
JP5201817B2 (ja) * 2005-10-28 2013-06-05 大塚製薬株式会社 医薬組成物
JP2009542818A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
JP2009542817A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
KR101040394B1 (ko) * 2010-05-18 2011-06-09 (주)이성산업 역화 방지 기능을 갖는 야외용 가스 히터
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
NZ718487A (en) * 2013-10-16 2020-01-31 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
US6492520B1 (en) * 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
AU763839B2 (en) * 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
JP2002517486A (ja) * 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
NZ510760A (en) * 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles

Also Published As

Publication number Publication date
ES2287107T3 (es) 2007-12-16
AR040075A2 (es) 2005-03-16
CN1422273A (zh) 2003-06-04
HK1052932A1 (en) 2003-10-03
PT1265900E (https=) 2007-08-22
HUP0204431A3 (en) 2006-01-30
PL358280A1 (en) 2004-08-09
AU2001239992B2 (en) 2005-09-01
CA2402092A1 (en) 2001-09-07
KR20020082858A (ko) 2002-10-31
NO20024134L (no) 2002-10-24
ZA200207017B (en) 2004-02-26
IL189865A0 (en) 2008-08-07
AR030053A1 (es) 2003-08-13
DK1265900T3 (da) 2007-09-24
JP2003525295A (ja) 2003-08-26
CA2402092C (en) 2012-01-24
EP1265900A1 (en) 2002-12-18
MXPA02008588A (es) 2003-02-24
DE60128457D1 (de) 2007-06-28
NZ520914A (en) 2004-03-26
EP1265900B1 (en) 2007-05-16
ATE362473T1 (de) 2007-06-15
IL151426A (en) 2011-01-31
CZ20022933A3 (cs) 2003-02-12
BR0108715A (pt) 2004-04-27
MY141144A (en) 2010-03-15
CN100482664C (zh) 2009-04-29
NO326409B1 (no) 2008-12-01
IL151426A0 (en) 2003-04-10
EP1265900A4 (en) 2004-11-10
NO20024134D0 (no) 2002-08-30
HUP0204431A1 (hu) 2003-04-28
DE60128457T2 (de) 2008-01-17
TWI290926B (en) 2007-12-11
KR100806978B1 (ko) 2008-02-25
CY1106816T1 (el) 2012-01-25
WO2001064679A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
AU3999201A (en) 1,5-disubstituted-3,4-dihydro-1h-pyrimido(4,5-d)pyrimidin-2- one compounds and their use in treating CSBP/P38 kinase mediated diseases
US5919813C1 (en) Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
NO20006090L (no) Pyrrolo(2,3d)pyrimidin sammensetninger og anvendelse herav
IL192338A0 (en) NOVEL 2,4,8-TRISUBSTITUTED-8h- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES
AU4562001A (en) Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
ZA200205097B (en) N-(5,7-dimethoxy[1,2,4]triazolo[1,5-A]pyrimidin-2-yl) arylsulfonamide compounds and their use as herbicides.
NO20021356D0 (no) Alkylendiamin-substituerte pyrazolo[1,5,-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner
NO20042676L (no) 3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
GB0016787D0 (en) Compounds useful in therapy
SG84620A1 (en) Disposable mask, and process for manufacturing the same
EP1248624A4 (en) 3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS
WO2004073628A3 (en) Novel compounds
IL158254A0 (en) Indolinones, substituted in position 6, and their use as kinase inhibitors
PT1326628E (pt) Mutantes de quimioquinas no tratamento de esclerose multipla
NO20030593D0 (no) Fremgangsmåter for behandling av cancer og smerten forbundet derved ved å anvende endotelinantagonister
PL365955A1 (en) Crf 2? ligands in combination therapy
Hawley Ashes of Immortality: Widow-Burning in India
NO20031588L (no) Substituerte 3,4-dihydro-pyrimido(1,2-a)pyrimidiner og 3,4- dihydropyrazino(1,2-a)pyrimidiner
GB0014046D0 (en) Compounds useful in therapy
EP1842851A3 (en) Novel compounds
ZA986050B (en) New triazolo (4,5-d)pyrimidine compounds and their use in medicaments
SI1325010T1 (en) Substituted 3.4-dihydro-pyrimido (1,2-a)pyrimidines and 3.4-dihydropyrazino (1,2-a)pyrimidines
GB0025582D0 (en) Benzimidazole compounds, their preparation and their use in therapy
AU2001247436A1 (en) Neutral antagonists and use thereof in treating drug abuse